QQQ   423.87 (-0.46%)
AAPL   166.80 (-0.71%)
MSFT   407.05 (-1.16%)
META   504.03 (+2.00%)
GOOGL   156.06 (+0.38%)
AMZN   179.39 (-1.04%)
TSLA   150.38 (-3.26%)
NVDA   843.77 (+0.41%)
AMD   153.98 (-0.03%)
NIO   4.03 (+3.07%)
BABA   68.98 (+0.23%)
T   16.20 (+0.50%)
F   12.03 (-0.08%)
MU   112.30 (-3.46%)
GE   154.69 (-0.63%)
CGC   7.75 (+19.41%)
DIS   113.05 (+0.10%)
AMC   2.91 (-2.35%)
PFE   25.27 (-0.59%)
PYPL   62.35 (-1.44%)
XOM   118.43 (-0.17%)
QQQ   423.87 (-0.46%)
AAPL   166.80 (-0.71%)
MSFT   407.05 (-1.16%)
META   504.03 (+2.00%)
GOOGL   156.06 (+0.38%)
AMZN   179.39 (-1.04%)
TSLA   150.38 (-3.26%)
NVDA   843.77 (+0.41%)
AMD   153.98 (-0.03%)
NIO   4.03 (+3.07%)
BABA   68.98 (+0.23%)
T   16.20 (+0.50%)
F   12.03 (-0.08%)
MU   112.30 (-3.46%)
GE   154.69 (-0.63%)
CGC   7.75 (+19.41%)
DIS   113.05 (+0.10%)
AMC   2.91 (-2.35%)
PFE   25.27 (-0.59%)
PYPL   62.35 (-1.44%)
XOM   118.43 (-0.17%)
QQQ   423.87 (-0.46%)
AAPL   166.80 (-0.71%)
MSFT   407.05 (-1.16%)
META   504.03 (+2.00%)
GOOGL   156.06 (+0.38%)
AMZN   179.39 (-1.04%)
TSLA   150.38 (-3.26%)
NVDA   843.77 (+0.41%)
AMD   153.98 (-0.03%)
NIO   4.03 (+3.07%)
BABA   68.98 (+0.23%)
T   16.20 (+0.50%)
F   12.03 (-0.08%)
MU   112.30 (-3.46%)
GE   154.69 (-0.63%)
CGC   7.75 (+19.41%)
DIS   113.05 (+0.10%)
AMC   2.91 (-2.35%)
PFE   25.27 (-0.59%)
PYPL   62.35 (-1.44%)
XOM   118.43 (-0.17%)
QQQ   423.87 (-0.46%)
AAPL   166.80 (-0.71%)
MSFT   407.05 (-1.16%)
META   504.03 (+2.00%)
GOOGL   156.06 (+0.38%)
AMZN   179.39 (-1.04%)
TSLA   150.38 (-3.26%)
NVDA   843.77 (+0.41%)
AMD   153.98 (-0.03%)
NIO   4.03 (+3.07%)
BABA   68.98 (+0.23%)
T   16.20 (+0.50%)
F   12.03 (-0.08%)
MU   112.30 (-3.46%)
GE   154.69 (-0.63%)
CGC   7.75 (+19.41%)
DIS   113.05 (+0.10%)
AMC   2.91 (-2.35%)
PFE   25.27 (-0.59%)
PYPL   62.35 (-1.44%)
XOM   118.43 (-0.17%)
Free Trial
LON:ETX

e-therapeutics (ETX) Share Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ETX Stock Alerts
GBX 9.55
-0.65 (-6.37%)
(As of 04:28 PM ET)
Compare
Today's Range
9.55
▼
10.20
50-Day Range
9.70
▼
16.55
52-Week Range
8
▼
24
Volume
1.07 million shs
Average Volume
548,226 shs
Market Capitalization
£55.80 million
P/E Ratio
N/A
Dividend Yield
3.35%
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlinesInsider Trades
ETX stock logo

About e-therapeutics Stock (LON:ETX)

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

ETX Stock Price History

ETX Stock News Headlines

April 18, 2024 | americanbankingnews.com
e-therapeutics (LON:ETX) Shares Cross Below 200-Day Moving Average of $11.94
April 11, 2024 | msn.com
Eliem Therapeutics to buy Tenet, announces $120 million private placement
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 10, 2024 | seekingalpha.com
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
April 10, 2024 | lse.co.uk
e-Therapeutics says company faces lack of interest as UK listing
April 10, 2024 | marketwatch.com
e-Therapeutics Shares Fall on London Delisting Plan; Mulls Move to New York
April 10, 2024 | msn.com
‘Lack of appetite’ in London drives another high-tech firm to Nasdaq
April 10, 2024 | msn.com
Drug discovery firm e-therapeutics to quit London Stock Exchange following £29m fundraise
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 16, 2024 | msn.com
Aquestive maps out FDA approval for sublingual anaphylaxis drug
January 3, 2024 | finance.yahoo.com
We're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash Wisely
December 27, 2023 | msn.com
Medical innovator e-therapeutics to stop trading on US-based market
November 13, 2023 | markets.businessinsider.com
Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
October 30, 2023 | businesswire.com
Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich
October 26, 2023 | proactiveinvestors.com
E-therapeutics bolsters generative AI integration and strategic...
September 28, 2023 | benzinga.com
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
September 28, 2023 | marketwatch.com
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold
September 20, 2023 | proactiveinvestors.com
e-therapeutics appoints new CFO
July 13, 2023 | uk.finance.yahoo.com
ETX.L - e-Therapeutics plc
June 8, 2023 | wsj.com
Elicio Therapeutics Inc.
May 23, 2023 | businesswire.com
AgeX Therapeutics Announces Appeal of NYSE American Determination
May 10, 2023 | businesswire.com
Rapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian Market
May 10, 2023 | marketwatch.com
Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001
May 6, 2023 | marketwatch.com
Acute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,Pfizer
May 4, 2023 | marketwatch.com
E-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D Costs
May 4, 2023 | finance.yahoo.com
e-Therapeutics working to capitalise on AI "blindside"
April 28, 2023 | markets.businessinsider.com
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
See More Headlines
Receive ETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/17/2020
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ETX
CUSIP
N/A
CIK
N/A
Web
www.etherapeutics.co.uk
Phone
+44-1993-880000
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-10,060,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.75%
Return on Assets
-29.10%

Debt

Debt-to-Equity Ratio
0.33
Current Ratio
22.20
Quick Ratio
20.13

Sales & Book Value

Annual Sales
£295,000.00
Price / Sales
197.15
Cash Flow
GBX 1.96 per share
Price / Cash Flow
5.07
Book Value
GBX 5 per share
Price / Book
1.99

Miscellaneous

Outstanding Shares
584,330,000
Free Float
N/A
Market Cap
£58.16 million
Optionable
Not Optionable
Beta
0.48
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Ahmad Ali Mortazavi (Age 53)
    CEO & Director
    Comp: $270k
  • Mr. Timothy Bretherton
    CFO, Director of Finance & Operations and Company Secretary
  • Dr. Laura Roca-Alonso Ph.D.
    Chief Operating & Business Officer
  • Mr. Alan Whitmore B.Sc.
    Ph.D., Chief Scientific Officer
  • Mr. Ankit Sharma
    Head of Software Engineering
  • Mr. Graham Craggs
    Head of Therapeutic Discovery

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ETX Stock Analysis - Frequently Asked Questions

How have ETX shares performed in 2024?

e-therapeutics' stock was trading at GBX 8.24 at the beginning of the year. Since then, ETX shares have increased by 15.9% and is now trading at GBX 9.55.
View the best growth stocks for 2024 here.

How were e-therapeutics' earnings last quarter?

e-therapeutics plc (LON:ETX) released its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.03.

What other stocks do shareholders of e-therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY).

How do I buy shares of e-therapeutics?

Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ETX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
1970’s computer coder issues shocking A.I. warning
TradeSmith
The Next Nvidia?
InvestorPlace
Options trading has suddenly become more reliable.
Eagle Publishing
AI healthcare stock poised for 36,996% growth?
Behind the Markets
Top 5 AI Stocks to Buy for 2024
Market Moving Trends